Melbourne, May 5, 2009 (ABN Newswire) - Benitec Limited (ASX:BLT)(PINK:BNIKF) is pleased to announce that the US Patent and Trademark Office ("USPTO") has recently withdrawn its novelty objection to Benitec's seminal RNAi interference US patent 6,573,099, often referred to as the "Graham" patent. This patent has been undergoing re-examination as outlined in previous announcements.
The only remaining objections of substance are two similar obviousness rejections based on a combination of the Carnegie Institute patent 6,506,559 with other documents. One rejection is for claim 4 and related claims, the other for claim 5 and related claims.
Sue MacLeman, CEO of Benitec, commented that "We are pleased that the USPTO has finally withdrawn the novelty rejection which had been based on what was, in our view, quite a different technology. We intend to move forward with the appeal process as quickly as possible."
It is likely that the next step for Benitec and its partner, CSIRO, is to elevate the re-examination to the Board of Patent Appeals and Interferences (BPAI) to overturn the obviousness rejections. In light of all of the material currently on the Patent Office file, CSIRO and Benitec remain confident of securing this patent. This next step is likely to take around 12 months and a decision is unlikely until 2010.
CSIRO and Benitec are continuing work on the remainder of their wide-ranging RNAi patent portfolio and commercialising the technology.
About Benitec Limited
Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio. Benitec is leveraging this platform to develop and build a pipeline of expressed RNAi therapeutics focusing on treatment and alleviation of cancer and infectious disease. With strong global partnerships and committed scientific and clinical investigators, Benitec Ltd aims to deliver a range of novel RNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry.
Contact
BENITEC LTD Sue MacLeman Chief Executive Officer TEL: +61-437-211-200
Benitec Limited
